The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of ∼5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate ≥30 to <90 mL/min/1.73 m 2, and albuminuria (urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (α = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An acute reduction in eGFR occurs with other classes of kidney-protective therapies, such as RAS inhibitors and SGLT2 inhibitors, and has been associated with long-term kidney protection (6,11,31,32).”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15,30,32]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationWorldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Research works printed but not linked: 1
- 3 International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels, Belgium, International Diabetes Federation, 2015.
Cited by
Items 201–251 of 251
Ezeani, I. U., Eregie, A., & Ohwovoriole, A. E. (2021) · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) · doi:10.30442/ahr.0703-02-131 · Cited by 2
The Effectiveness of SGLT2 Inhibitors in CKD Patients
Boddula, H., Shivani, R., Nayak, S. P. S., Vaghasia, J., Chakraborthy, G. S., Mandal, S. D., & Ghatol, P. W. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i3.5750 · Cited by 2
Tsoukas, M. A., Woo, V. C., Tobe, S. W., Slee, A. E., Rapattoni, W., Ang, F. G., Seufert, J., Neuen, B. L., Arnott, C. G., Mahaffey, K. W., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15057 · Cited by 2
Self-citationKato, S., Kuwatsuka, Y., Ando, M., Tatematsu, Y., Nishibori, N., & Maruyama, S. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03277-0 · Cited by 2
Predicting Chronic Kidney Disease Progression from Stage III to Stage V using Language Models
Awan, Z., Henkin, R., Reynolds, N. J., & Michael, B. (2025) · Workshop on Patient-Oriented Language Processing (CL4Health) · doi:10.18653/v1/2025.cl4health-1.20 · Cited by 2
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Niezen, S., del Castillo, H. D., Castaner, L. A. M., & Fornoni, A. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.72 · Cited by 2
Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications
Hussein, M. T. E., & Bell, N. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.09.002 · Cited by 2
Vícha, M., Skála, T., Jelínek, L., Pavlů, L., Jarkovský, J., Dušek, L., Benešová, K., & Táborský, M. (2021) · Biomedical Papers · doi:10.5507/bp.2021.069 · Cited by 2
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2 · Cited by 1
Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease
Hu, D., Chen, L., Mai, R., Gao, T., & Guan, B. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2667611 · Cited by 1
Glycemic Control and Future Perspectives for Treatment
Miyamoto, S., & Shikata, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_6 · Cited by 1
Ferraro, R., NASS, C. M., Dudum, R., Blumenthal, R. S., & Sarkar, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.050 · Cited by 1
Hussein, N., Abdelrahman, F., Khedr, A., Aref, H. M., Halawa, M. R., & Elsharkawy, M. M. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999201110194413 · Cited by 1
The position of SGLT2 inhibitors in current medical practice - update 2022
Prázný, M. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.019 · Cited by 1
Pomegranate for Diabetes and its’ Complications Amelioration
Stefanou, V. (2022) · International Journal of Pharmaceutical and Bio-Medical Science · doi:10.47191/ijpbms/v2-i8-03 · Cited by 1
Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison
Sciatti, E., & Ceconi, C. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320913381 · Cited by 1
Reply: Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862262 · Cited by 1
Saad, M., Gomceli, U., Ravi, P., Lacoste, A. G., Shah, N., & Vittorio, T. J. (2018) · Drugs in Context · doi:10.7573/dic.212549
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
Herrington, W. G., Zhu, D., & Haynes, R. (2019) · Annals of Internal Medicine · doi:10.7326/acpj201902190-015
The Ups and Downs of Non-Insulin Therapies: The Agony of Choice
Chen, R., & Munsif, A. (2019) · Clinical Management Issues · doi:10.7175/cmi.v13i1.1426
The position of SGLT2 inhibitors in current medicine
Prázný, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.013
Importance of modern antidiabetic drugs for the cardiologist and diabetologist
Šmahelová, A. (2020) · Intervenční a akutní kardiologie · doi:10.36290/kar.2020.025
Rocha, N. A., & McCullough, P. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_8
多層構造ダイヤモンド膜製ナノマニピュレータの研究(マイクロ・ナノ作業1)
関根, 吾., 中里, 裕., 宮澤, 肇., 竹内, 貞., 有賀, 幸., & 村川, 正. (2004) · The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
GARGALLO-FERNANDEZ, M. A., Sanz-Pastor, A. G., Antón-Bravo, T., Brito-Sanfiel, M. Á., WONG-CRUZ, J. E. M., & Martínez, J. J. G. (2021) · Diabetology · doi:10.3390/diabetology2030015
(2017) · American Journal of Nephrology · doi:10.1159/000486151
(2021) · ADA Clinical Compendia · doi:10.2337/db20211-34
SGLT-2-Inhibitoren — neues Wundermittel zur Behandlung des Diabetes mellitus Typ 2?
Sönnichsen, A. C. (2018) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652232
Canagliflozin bei diabetischer Nierenerkrankung
Pavlicek, V. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01110-8
Lifestyle and socio-economic inequalities in diabetes prevalence in Madadeni Township, South Africa
Mposula, Z. A., Pacza, T., Szepesi, J., & Máthé, E. (2023) · Acta Medicinae et Sociologica · doi:10.19055/ams.2023.12/15/1
Zengul, F. D., Lee, T., Delen, D., Almehmi, A., Ivankova, N. V., Mehta, T., & Topuz, K. (2019) · Figshare · doi:10.6084/m9.figshare.11365115
Kłusek, M., Chawrylak, K., Kuszneruk, J., Kubas, M., & Krzemińska, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.18.53252
Actualización en factores de riesgo cardiovascular y diabetes mellitus
Lachica, L. Á., & García, M. D. C. G. (2024) · Diabetes práctica · doi:10.52102/diabet/pract.2024.2.art1
Orsi, E., & Resi, V. (2020) · La Medicina del Lavoro · doi:10.23749/mdl.v110i2-s.9741
Waheed, A., Beaulieu, M., Weber, C. L., Zalunardo, N., & Levin, A. (2015) · Oxford University Press eBooks · doi:10.1093/med/9780199592548.003.0097_update_001
Self-citationMahesar, A. L., Babu, V., Dero, M., memon, T., Kumar, S., Hayat, A., gul, N., Khan, M. S., Kiran, S., Kumari, A., et al. (2025) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/8vp1s226
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Beyazıt, Y., Ertekin, Y. H., Kurtkulağı, Ö., & Pek, E. (2024) · doi:10.55094/holistence.237
Khalid, K., Ali, M. M., Islam, F., Hasan, S., Saeed, S., & Perveen, S. (2025) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/mzmf6t81
Kato, S., Kuwatsuka, Y., Ando, M., Tatematsu, Y., Nishibori, N., & Maruyama, S. (2023) · Figshare · doi:10.6084/m9.figshare.23849510
Mohebi, R., Liu, Y., Hansen, M. K., Yavin, Y., Sattar, N. A., Pollock, C. A., Butler, J., Jardine, M., Masson, S., Heerspink, H. J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23672663
Self-citationImproving the Uptake of Evidence-based Therapy in Chronic Kidney Disease and Diabetes
Yi, T. W. (2024) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/30079
Bramlage, P., Lanzinger, S., Mühldorfer, S., Milek, K., Gillessen, A., Veith, R., Ohde, T., Danne, T., Holl, R. W., & Seufert, J. (2023) · Figshare · doi:10.6084/m9.figshare.22790519
Kato, S., Kuwatsuka, Y., Ando, M., Tatematsu, Y., Nishibori, N., & Maruyama, S. (2023) · Figshare · doi:10.6084/m9.figshare.23849513
Zhang, Y., Xie, J.-J., Wu, Q., Zhou, X., Zeng, C., Zeng, Y., He, Y.-M., Guo, M., Teng, F.-Y., & Xu, Y. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02300-6
Self-citationEurasian clinical guidelines for the diagnosis and treatment of cardiorenal syndrome (2026)
Mitkovskaya, N. P., Chazova, I. E., Sudzhaeva, O. A., Grigorenko, E., Калачик, О. В., Геннадьевна, Ш. Л., Бранковская, Е. Ю., Смолякова, М. В., Trushina, O. I., Podzolkov, V. I., et al. (2026) · Eurasian heart journal · doi:10.38109/2225-1685-2026-2-6-41
Dey, S., Saha, S., Mandal, D., Maity, R., Mir, U. B., Chowdhury, S. R., Kundu, S., & Saha, L. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.62s.99
Евразийские клинические рекомендации по диагностике и лечению кардиоренального синдрома (2026)
П., М. Н., Чазова, И. Е., А., С. О., Григоренко, Е. А., В., К. О., Г., Ш. Л., Ю., Б. Е., В., С. М., Юрьевна, Т. О., И., П. В., et al. (2026) · Eurasian heart journal
de la Rambelje, M. A., Nair, V., Jongs, N., Menon, R., Otto, E. A., Hansen, M. K., Bjornstad, P., Kretzler, M., Voors, A. A., Ju, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71518
Self-citation
Metadata
- Authors
- Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Pollock, C., Wheeler, D. C., Xie, J., Zhang, H., Zinman, B., Desai, M., Perkovic, V., & on behalf of the CREDENCE study investigators
- Affiliations
- The University of Sydney (AU)
- Stanford Medicine (US)
- Richard L. Roudebush VA Medical Center (US)
- University of Chicago (US)
- Brigham and Women's Hospital (US)
- Janssen Research & Development (United States) (US)
- University of Utah (US)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University College London (GB)
- Peking University First Hospital (CN)
- Mount Sinai Hospital (CA)
- UNSW Sydney (AU)
- ORCID
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 46
- Issue
- 6
- Pages
- 462-472
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- PMC
- PMC5804835
- OpenAlex
- W2772844083
- Cited by
- 234
- References
- 32
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 15 · 2023: 25 · 2022: 16 · 2021: 27 · 2020: 45 · 2019: 51 · 2018: 40 · 2017: 2
- FWCI
- 33.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- American Journal of Nephrology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, diabetic nephropathy, albuminuria, end-stage renal disease, cardiovascular outcomes, renal outcomes, CREDENCE trial, trial design, baseline characteristics
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.